XENOTHERA
5.1.2023 18:01:38 CET | Business Wire | Press release
In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA announces recent data in favor of the strong interest of its glyco-humanized polyclonal antibody (GH-pAb) XAV-19 to treat patients in the initial viral phase of the disease.
Several neutralization assays carried out by XENOTHERA have supplemented data already published (Vanhove et al. 2020, 2021, 2022). XAV-19 exhibits a strong neutralization activity against all omicron variants, including BQ.1.1, the main variant of SARS-CoV-2 in circulation to date. In the meantime, all monoclonal antibodies today marketed lose their activity against this variant. The neutralizing concentration of XAV-19 (IC50) is identical to that measured for all other variants of SARS-CoV-2.
XAV-19 is in clinic since 2020, with more than 700 patients having participated in trials in France, Bulgaria, Spain, Romania, Greece, and Turkey. The biotech has recently released the first results of its phase II/III clinical trial EUROXAV, suspended due to a low enrollment. Preliminary analysis show that XAV-19 tends to improve the recovery rate and to lower the aggravation risk for moderate patients at WHO score 2, within 6 days after symptoms onset. No safety issue has been raised during the trials.
PK data from patients treated with XAV-19 show a trough level ten times higher than the IC50 (Gaborit et al. 2021). In total, one single injection of XAV-19 is likely to neutralize the BQ.1.1 virus or any other variant during the viral phase of the disease.
Considering the current pandemic situation where there is no remaining therapeutic solution for immuno-compromised patients, for whom the administration of anti-COVID antibodies is essential, XAV-19 from XENOTHERA seems to be one of the most promising candidates to address this medical need.
In parallel, the biotech goes on with 3 products in clinic today and an attractive oncology portfolio.
"Today we reiterate our commitment for serving patients and the medical community. While COVID persists as a life-threatening concern, XAV-19 should be considered, in view of its safety and efficacy, particularly on variants, as a viable therapeutic solution for immunocompromised individuals who do not produce their own antibodies. In view of the benefit/risk ratio, we are more than ever ready to move quickly to make XAV-19 available to physicians and patients. In the meantime, we develop further our whole portfolio, particularly in oncology where unmet medical needs are huge also." comments Odile Duvaux, CEO and co-founder of XENOTHERA.
*****************
About XENOTHERA:
Founded in 2014, XENOTHERA is a Nantes-based biotech that develops new therapeutic modes in many fields (immunology, oncology, viral infections...). The company develops treatments based on a unique proprietary technology of "glyco-humanized polyclonal antibodies (GH-pAb)”. Its technological platform is built on a dual expertise in genetics and immunology.
The biotech has a complete portfolio of products, including three products in clinic: LIS1, an immunosuppressant for solid organ transplantation; XAV-19, an anti-Covid treatment for patients with moderate disease; and XAB05, for the prevention and treatment of multi-drug resistant bacterial infections.
XENOTHERA, is part of the scientific and medical environment of the Pays de la Loire (France). The company has raised 43M€ since its creation, its main investors are the Pays de la Loire Region, BPI France and the European EIC Fund.
More information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005061/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria3.3.2026 14:00:00 CET | Press release
Partnership marks a critical step toward clinical development of an AAV gene therapy using a base editing approach designed to target the genetic cause of Hutchinson-Gilford Progeria SyndromeForge Biologics will provide process development and manufacturing expertise to support gene therapy advancement led by world-renowned researchers Leslie Gordon, David Liu, and Francis Collins The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a manufacturing agreement to support the development and manufacturing of SamPro-2, PRF’s investigational gene therapy for children and young adults living with Progeria, an ultrarare and fatal genetic disease characterized by rapid aging. This press release features multimedia. View the full
PAX Unveils Long-Anticipated PAX FOUR, Its Most Powerful Dry Herb Vaporizer Yet3.3.2026 14:00:00 CET | Press release
Designed for denser vapor and immediate impact without combustion, FOUR delivers smoking-level intensity in a precision-engineered, portable device Nearly two decades after defining the category, PAX today announced the launch of PAX FOUR, the most powerful dry herb vaporizer in the company’s history. Built for consumers who want dense vapor and immediate impact without combustion, PAX FOUR delivers smoking-level intensity you can see and feel in a sleek, precision-engineered device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740648/en/ PAX FOUR, the most powerful dry herb vaporizer in the company’s history. The cannabis vaporization category continues to grow as consumers shift away from smoking and combustion, yet many remain loyal to traditional smoking methods, often citing weak vapor, lack of intensity, and inconsistent performance from existing devices. PAX FOUR was engineered to change that — producing large
Riskified Announces Expansion of AI Agent Intelligence to Secure Native Merchant AI Shopping Assistants3.3.2026 14:00:00 CET | Press release
Amidst the growing adoption of native AI agents and chatbots on retail websites, Riskified leverages its unique data infrastructure to help merchants deploy highly personalized, secure AI shopping assistants Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced an expansion of its AI Agent Intelligence platform, positioning the company as the definitive shield for the next era of ecommerce. As merchants explore deploying their own native, conversational AI shopping assistants to elevate their customer experience, Riskified is ensuring that these new touchpoints are protected from sophisticated fraud and abuse. Retailers are heavily investing in bringing AI agents directly to their digital storefronts. Research from McKinsey & Company underscores this trend, noting that 82% of retail organizations have already launched generative AI pilots focused on reinventing customer service. As merchants build out their AI shopping assistants to offer deep perso
Jackson County REMC brings ultra-fast fiber to rural Indiana with Adtran3.3.2026 14:00:00 CET | Press release
News summary: Rural electric co-op needed a scalable, easy-to-manage network with transparent pricing, real-time insights and faster troubleshooting Adtran’s fiber access, Wi-Fi and cloud management technology supports expansion into underserved areas and rapid fault resolution Solution delivers 20-30% cost savings, improved subscriber experience and greater operational efficiency Adtran today announced that Jackson County REMC is transforming its broadband network with Adtran technology to help close the digital divide and bring faster, more reliable connectivity to homes, businesses and farms across southern Indiana. The member-owned electric co-op selected Adtran for its transparent approach and collaborative partnership, moving away from restrictive models that added complexity and cost. The integrated solution combines fiber access, AI-driven Mosaic One SaaS and Intellifi® managed Wi‑Fi to reduce truck rolls and lower operating expenses by up to 30%. This empowers Jackson County R
Armis Launches Marketplace to Help Security Teams Accelerate and Optimize Integrated Technology Stacks3.3.2026 14:00:00 CET | Press release
Self-service portal enables organizations to instantly access and deploy trusted partner integrations, tools and services Armis, the cyber exposure management & security company, today announced Armis Marketplace, a digital hub for security teams to find, evaluate and implement solutions that seamlessly integrate with their existing Armis deployments. The portal's centralized access to trusted partner integrations empowers Armis customers to more quickly validate the effectiveness of solutions within their own environments. “The real bottleneck for security teams today is not discovering new tools or services but the friction of validating them,” said Nadir Izrael, CTO and Co-Founder at Armis. “The Armis Marketplace is designed for action, enabling teams to significantly cut purchasing time from weeks to hours and move from proof to deployment in record time. This allows organizations to secure their environment and focus on what matters most.” Unlike traditional marketplaces that simp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom